Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD + trastuzumab + paclitaxel neoadjuvant study in HER2-positive breast cancer
ChiCTR1800016222Phase 4Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab and paclitaxel in breast cancer, sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: pathologic complete response rate. Started May 2018; status: recruiting.
02
Drugs
trastuzumabpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800016222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016222.